{"test_cases_lookup_map": {"{\"actual_output\": \"No relevant information available.\", \"context\": null, \"expected_output\": \"Neuralink chips feature thousands of electrodes, real-time signal processing, wireless communication capabilities, rechargeable batteries, and advanced neural signal amplification.\", \"hyperparameters\": null, \"input\": \"What are the technical specifications of Neuralink chips?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"**Key Features:**\\n\\n* Sensor array: 128-channel dry EEG with adaptive calibration\\n* Latency: <15 ms brain-to-command response time\\n* AI interpretation: Deep-learning\\u2013based decoding for motor, cognitive, and emotional states\\n* Battery life: 22 hours continuous operation\\n* Connectivity: Secure 5G, Wi-Fi 6, and BLE integration\\n* Compatibility: Works across iOS, Android, Windows, and VR/AR ecosystems\\n\\n---\\n\\n### **Technology Platform**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": false, "score": 0.0, "reason": "The score is 0.00 because the response did not provide any technical specifications of Neuralink chips and only stated that no information is available, making it completely irrelevant to the question.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"No relevant information available.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The statement does not provide any technical specifications of Neuralink chips; it only states that no information is available.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"The sensor array consists of a 128-channel dry EEG with adaptive calibration.\",\n    \"The device has a brain-to-command response time latency of less than 15 milliseconds.\",\n    \"AI interpretation uses deep-learning\u2013based decoding for motor, cognitive, and emotional states.\",\n    \"The battery life allows for 22 hours of continuous operation.\",\n    \"Connectivity options include secure 5G, Wi-Fi 6, and BLE integration.\",\n    \"The device is compatible with iOS, Android, Windows, and VR/AR ecosystems.\",\n    \"The company is named NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"The headquarters of NeuroLink Systems Inc. is in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[] \n \nVerdicts:\n[]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"The SynapseBand uses multi-sensor arrays and NeuroLink's NeuralNet Engine to translate thought patterns into digital commands.\", \"context\": null, \"expected_output\": \"Data from Neuralink devices is transmitted wirelessly using Bluetooth technology to external devices like smartphones or computers for processing and control.\", \"hyperparameters\": null, \"input\": \"How is data transmitted from Neuralink devices?\", \"retrieval_context\": [\"---\\n\\n### **Flagship Product: SynapseBand\\u2122**\\n\\nThe SynapseBand is a wearable, non-invasive neural headband that detects and decodes neural activity in real time. It leverages multi-sensor arrays and NeuroLink\\u2019s proprietary NeuralNet Engine\\u2122 to translate thought patterns into actionable digital commands.\\n\\n**Key Features:**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": false, "score": 0.3333333333333333, "reason": "The score is 0.33 because the answer discusses hardware and processing components unrelated to the specific question about data transmission from Neuralink devices, thus failing to directly address the core of the input.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"The SynapseBand uses multi-sensor arrays.\",\n    \"The SynapseBand uses NeuroLink's NeuralNet Engine.\",\n    \"The device translates thought patterns into digital commands.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The statement describes the SynapseBand's hardware (multi-sensor arrays), but does not address how data is transmitted from Neuralink devices.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement refers to the use of a NeuralNet Engine, which may relate to processing, but does not explain the data transmission method from Neuralink devices.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"The SynapseBand is a wearable, non-invasive neural headband.\",\n    \"The SynapseBand detects and decodes neural activity in real time.\",\n    \"The SynapseBand uses multi-sensor arrays.\",\n    \"The SynapseBand uses NeuroLink\u2019s proprietary NeuralNet Engine to translate thought patterns into digital commands.\",\n    \"The SynapseBand NeuroRehab Protocol received FDA Breakthrough Device Designation in 2022.\",\n    \"NeuroLink SDK 2.0 was launched for developers in Q2 2023.\",\n    \"NeuroLink partnered with Meta for brain-controlled VR experiences in Q4 2023.\",\n    \"NeuroLink closed a Series E funding round of $310 million led by Andreessen Horowitz and SoftBank Vision Fund in Q1 2024.\",\n    \"NeuroLink published peer-reviewed results in Nature Neuroscience, Vol. 29, Issue 7.\"\n] \n \nClaims:\n[\n    \"The SynapseBand uses multi-sensor arrays and NeuroLink's NeuralNet Engine to translate thought patterns into digital commands.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"No relevant information available.\", \"context\": null, \"expected_output\": \"Neuralink has received FDA approval for human trials and has begun recruiting participants for studies focused on helping paralyzed individuals control digital devices.\", \"hyperparameters\": null, \"input\": \"What is the current status of Neuralink clinical trials?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the question directly without any irrelevant information. Great job staying focused and concise!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"No relevant information available.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink Systems Inc. received FDA Breakthrough Device Designation for the SynapseBand NeuroRehab Protocol in 2022.\",\n    \"NeuroLink Systems Inc. launched NeuroLink SDK 2.0 for developers in the second quarter of 2023.\",\n    \"NeuroLink Systems Inc. partnered with Meta for brain-controlled VR experiences in the fourth quarter of 2023.\",\n    \"NeuroLink Systems Inc. closed a Series E funding round of $310 million led by Andreessen Horowitz and SoftBank Vision Fund in the first quarter of 2024.\",\n    \"NeuroLink Systems Inc. published peer-reviewed results in Nature Neuroscience, Volume 29, Issue 7.\",\n    \"The company name is NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"NeuroLink Systems Inc. is headquartered in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[] \n \nVerdicts:\n[]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"NeuroLink Systems Inc. is a neurotechnology company pioneering the next generation of brain\\u2013computer interfaces (BCIs). By combining advanced neuroimaging, signal processing, and AI-driven interpretation, NeuroLink enables seamless communication between the human brain and digital systems.\", \"context\": null, \"expected_output\": \"The Neuralink BCI uses ultra-thin threads with electrodes to record neural activity. These threads are surgically implanted by a robot, and the signals are processed by a chip that wirelessly transmits data.\", \"hyperparameters\": null, \"input\": \"How does the Neuralink brain-computer interface work?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **Overview**\\n\\nNeuroLink Systems Inc. is a neurotechnology company pioneering the next generation of brain\\u2013computer interfaces (BCIs).\\nBy combining advanced neuroimaging, signal processing, and AI-driven interpretation, NeuroLink enables seamless communication between the human brain and digital systems. The company\\u2019s solutions empower patients, clinicians, and innovators to extend cognition, restore neurological function, and build new modes of human\\u2013machine collaboration.\\n\\n---\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 0.75, "reason": "The score is 0.75 because the answer partially addresses the question by identifying the company, but it does not explain how the Neuralink brain-computer interface works, which is what was asked. The score is not lower because at least the relevant company is mentioned, but it can't be higher due to the lack of an actual explanation.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"NeuroLink Systems Inc. is a neurotechnology company.\",\n    \"The company is pioneering the next generation of brain\u2013computer interfaces (BCIs).\",\n    \"NeuroLink combines advanced neuroimaging, signal processing, and AI-driven interpretation.\",\n    \"NeuroLink enables seamless communication between the human brain and digital systems.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement only identifies the company and does not explain how the Neuralink brain-computer interface works.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully aligned with the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink Systems Inc. is a neurotechnology company.\",\n    \"NeuroLink Systems Inc. works on brain\u2013computer interfaces (BCIs).\",\n    \"The company combines neuroimaging, signal processing, and AI-driven interpretation in its technology.\",\n    \"NeuroLink Systems Inc. enables communication between the human brain and digital systems.\",\n    \"The company's solutions are used by patients, clinicians, and innovators.\",\n    \"NeuroLink Systems Inc. aims to extend cognition, restore neurological function, and build new modes of human\u2013machine collaboration.\",\n    \"The company was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"The company is headquartered in San Francisco, California.\",\n    \"The company's mission is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[\n    \"NeuroLink Systems Inc. is a neurotechnology company pioneering the next generation of brain\u2013computer interfaces (BCIs).\",\n    \"NeuroLink combines advanced neuroimaging, signal processing, and AI-driven interpretation.\",\n    \"NeuroLink enables seamless communication between the human brain and digital systems.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"NeuroLink Systems Inc. is a company that specializes in safe, non-invasive neural interface technologies. Their flagship product, SynapseBand, is FDA-cleared for clinical use and has passed IEC 60601 safety standards. It is also available for consumer wellness markets. Independent trials have reported a high accuracy rate of 93-96% for the thought-to-command system.\", \"context\": null, \"expected_output\": \"Safety considerations include biocompatibility of materials, minimizing infection risk, long-term stability, avoiding immune reactions, and ensuring the surgical procedure is safe.\", \"hyperparameters\": null, \"input\": \"What are the safety considerations for Neuralink implants?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **FAQs**\\n\\n**Q: Is SynapseBand safe for everyday use?**\\nA: Yes. SynapseBand is non-invasive, FDA-cleared for clinical use, and has passed IEC 60601 safety standards.\\n\\n**Q: Can SynapseBand be used outside hospitals?**\\nA: Absolutely. SynapseBand is available for both clinical and consumer wellness markets.\\n\\n**Q: How accurate is the thought-to-command system?**\\nA: Independent trials report 93\\u201396% accuracy across motor intention, focus detection, and emotional state classification.\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": false, "score": 0.5, "reason": "The score is 0.50 because the answer mentions facts about Neuralink's product and performance, but does not address the specific safety considerations asked about. The inclusion of unrelated information about product availability and accuracy detracts from the relevance, but some context about Neuralink is provided, which is why the score is not lower.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"NeuroLink Systems Inc. specializes in safe, non-invasive neural interface technologies.\",\n    \"The flagship product of NeuroLink Systems Inc. is SynapseBand.\",\n    \"SynapseBand is FDA-cleared for clinical use.\",\n    \"SynapseBand has passed IEC 60601 safety standards.\",\n    \"SynapseBand is available for consumer wellness markets.\",\n    \"Independent trials have reported a high accuracy rate of 93-96% for the thought-to-command system.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The statement only identifies the flagship product and does not address safety considerations.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"Availability in consumer wellness markets does not address safety considerations.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"Accuracy rate of the system is about performance, not safety.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"The company is named NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"Dr. Amara Venkatesh is the founder and CEO of NeuroLink Systems Inc.\",\n    \"The headquarters of NeuroLink Systems Inc. is in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\",\n    \"SynapseBand is a product associated with NeuroLink Systems Inc.\",\n    \"SynapseBand is non-invasive.\",\n    \"SynapseBand is FDA-cleared for clinical use.\",\n    \"SynapseBand has passed IEC 60601 safety standards.\",\n    \"SynapseBand is available for both clinical and consumer wellness markets.\",\n    \"Independent trials report that the thought-to-command system of SynapseBand has 93\u201396% accuracy across motor intention, focus detection, and emotional state classification.\"\n] \n \nClaims:\n[\n    \"NeuroLink Systems Inc. is a company that specializes in safe, non-invasive neural interface technologies.\",\n    \"NeuroLink Systems Inc.'s flagship product is SynapseBand.\",\n    \"SynapseBand is FDA-cleared for clinical use.\",\n    \"SynapseBand has passed IEC 60601 safety standards.\",\n    \"SynapseBand is available for consumer wellness markets.\",\n    \"Independent trials have reported a high accuracy rate of 93-96% for the thought-to-command system.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"Neuralink's mission is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies. While the company has not yet released any specific medical treatments, their technology has the potential to treat a wide range of neurological conditions.\", \"context\": null, \"expected_output\": \"Neuralink aims to treat paralysis, spinal cord injuries, depression, anxiety, memory loss, stroke effects, and other neurological and psychiatric conditions.\", \"hyperparameters\": null, \"input\": \"What medical conditions can Neuralink potentially treat?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"**Q: Can developers build apps for the platform?**\\nA: Yes, through the NeuroLink SDK and open API marketplace.\\n\\n---\\n\\n### **Media Contacts**\\n\\n[press@neurolink.com](mailto:press@neurolink.com)\\n[investors@neurolink.com](mailto:investors@neurolink.com)\\n\\n---\\n\\n**Company Motto:** *\\u201cWhere Thought Meets Possibility\\u2122\\u201d*\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 0.75, "reason": "The score is 0.75 because the answer mentions the lack of specific treatments but does not directly address which medical conditions Neuralink could potentially treat, making the response only partially relevant.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Neuralink's mission is to unlock the full potential of the human brain.\",\n    \"Neuralink aims to achieve this through safe, non-invasive neural interface technologies.\",\n    \"The company has not yet released any specific medical treatments.\",\n    \"Neuralink's technology has the potential to treat a wide range of neurological conditions.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement only says that no specific treatments have been released, but does not address what conditions Neuralink could potentially treat.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": false, "score": 0.6666666666666666, "reason": "The score is 0.67 because the actual output confuses 'Neuralink' with 'NeuroLink Systems Inc.', using a mission statement from the latter, which is a different company, leading to a partial contradiction.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"The company name is NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"The headquarters of NeuroLink Systems Inc. is in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\",\n    \"Developers can build apps for the NeuroLink platform through the NeuroLink SDK and open API marketplace.\",\n    \"The company motto is 'Where Thought Meets Possibility\u2122'.\",\n    \"The press contact email for NeuroLink Systems Inc. is press@neurolink.com.\",\n    \"The investor contact email for NeuroLink Systems Inc. is investors@neurolink.com.\"\n] \n \nClaims:\n[\n    \"Neuralink's mission is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\",\n    \"The company has not yet released any specific medical treatments.\",\n    \"Neuralink's technology has the potential to treat a wide range of neurological conditions.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The claim refers to 'Neuralink', but the retrieval context is about 'NeuroLink Systems Inc.', which is a different company. The mission statement provided is for NeuroLink Systems Inc., not Neuralink.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"Neuralink has achieved several recent milestones, including receiving FDA Breakthrough Device Designation for their SynapseBand NeuroRehab Protocol in 2022, launching their NeuroLink SDK 2.0 for developers in Q2 2023, partnering with Meta for brain-controlled VR experiences in Q4 2023, and closing a Series E funding round of $310M led by Andreessen Horowitz and SoftBank Vision Fund in Q1 2024. They have also published peer-reviewed results in Nature Neuroscience, Vol. 29, Issue 7.\", \"context\": null, \"expected_output\": \"Recent Neuralink milestones include successful human trials, FDA breakthrough device designation, improved chip performance, and progress in treating paralysis and neurological conditions.\", \"hyperparameters\": null, \"input\": \"What are the recent milestones achieved by Neuralink?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the question directly without any irrelevant information. Great job staying focused and informative!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Neuralink received FDA Breakthrough Device Designation for their SynapseBand NeuroRehab Protocol in 2022.\",\n    \"Neuralink launched their NeuroLink SDK 2.0 for developers in Q2 2023.\",\n    \"Neuralink partnered with Meta for brain-controlled VR experiences in Q4 2023.\",\n    \"Neuralink closed a Series E funding round of $310M led by Andreessen Horowitz and SoftBank Vision Fund in Q1 2024.\",\n    \"Neuralink published peer-reviewed results in Nature Neuroscience, Vol. 29, Issue 7.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": false, "score": 0.0, "reason": "The score is 0.00 because the actual output repeatedly attributes key achievements and events to Neuralink instead of NeuroLink Systems Inc., directly contradicting the retrieval context in every listed instance.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink Systems Inc. received FDA Breakthrough Device Designation for the SynapseBand NeuroRehab Protocol in 2022.\",\n    \"NeuroLink Systems Inc. launched NeuroLink SDK 2.0 for developers in the second quarter of 2023.\",\n    \"NeuroLink Systems Inc. partnered with Meta for brain-controlled VR experiences in the fourth quarter of 2023.\",\n    \"NeuroLink Systems Inc. closed Series E funding of $310 million led by Andreessen Horowitz and SoftBank Vision Fund in the first quarter of 2024.\",\n    \"NeuroLink Systems Inc. published peer-reviewed results in Nature Neuroscience, Volume 29, Issue 7.\",\n    \"The company name is NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"NeuroLink Systems Inc. is headquartered in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[\n    \"Neuralink received FDA Breakthrough Device Designation for their SynapseBand NeuroRehab Protocol in 2022.\",\n    \"Neuralink launched their NeuroLink SDK 2.0 for developers in Q2 2023.\",\n    \"Neuralink partnered with Meta for brain-controlled VR experiences in Q4 2023.\",\n    \"Neuralink closed a Series E funding round of $310M led by Andreessen Horowitz and SoftBank Vision Fund in Q1 2024.\",\n    \"Neuralink published peer-reviewed results in Nature Neuroscience, Vol. 29, Issue 7.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The retrieval context states that NeuroLink Systems Inc., not Neuralink, received FDA Breakthrough Device Designation for the SynapseBand NeuroRehab Protocol in 2022.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The retrieval context states that NeuroLink Systems Inc., not Neuralink, launched NeuroLink SDK 2.0 for developers in Q2 2023.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The retrieval context states that NeuroLink Systems Inc., not Neuralink, partnered with Meta for brain-controlled VR experiences in Q4 2023.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The retrieval context states that NeuroLink Systems Inc., not Neuralink, closed a Series E funding round of $310M led by Andreessen Horowitz and SoftBank Vision Fund in Q1 2024.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The retrieval context states that NeuroLink Systems Inc., not Neuralink, published peer-reviewed results in Nature Neuroscience, Vol. 29, Issue 7.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"Neuralink faces challenges in development such as ensuring the safety and efficacy of their neural interface technologies, obtaining regulatory approvals, and developing partnerships for commercialization.\", \"context\": null, \"expected_output\": \"Neuralink faces challenges including regulatory approval, ensuring long-term biocompatibility, scaling manufacturing, addressing ethical concerns, and proving clinical efficacy.\", \"hyperparameters\": null, \"input\": \"What challenges does Neuralink face in development?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the challenges Neuralink faces in development without including any irrelevant information. Great job staying focused and on-topic!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Neuralink faces challenges in development.\",\n    \"Ensuring the safety and efficacy of their neural interface technologies is a challenge for Neuralink.\",\n    \"Obtaining regulatory approvals is a challenge for Neuralink.\",\n    \"Developing partnerships for commercialization is a challenge for Neuralink.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink Systems Inc. received FDA Breakthrough Device Designation for the SynapseBand NeuroRehab Protocol in 2022.\",\n    \"NeuroLink Systems Inc. launched NeuroLink SDK 2.0 for developers in the second quarter of 2023.\",\n    \"NeuroLink Systems Inc. partnered with Meta for brain-controlled VR experiences in the fourth quarter of 2023.\",\n    \"NeuroLink Systems Inc. closed a Series E funding round of $310 million led by Andreessen Horowitz and SoftBank Vision Fund in the first quarter of 2024.\",\n    \"NeuroLink Systems Inc. published peer-reviewed results in Nature Neuroscience, Volume 29, Issue 7.\",\n    \"The company name is NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"NeuroLink Systems Inc. is headquartered in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[\n    \"Neuralink faces challenges in development such as ensuring the safety and efficacy of their neural interface technologies, obtaining regulatory approvals, and developing partnerships for commercialization.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}}}